GlassScriptPhysician profile
Lubna Khan
NPI 1417033044
$3,821.26
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $379 · 2021: $1,018 · 2022: $995 · 2023: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $801.65 | 2019-2023 | Farxiga, Breztri, Bevespi Aerosphere |
| Abbvie INC. | $443.79 | 2020-2023 | |
| Pfizer INC. | $426.72 | 2019-2023 | |
| Novo Nordisk INC | $376.13 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.42 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $225.14 | 2019-2023 | Steglatro, Janumet, Januvia |
| Biohaven Pharmaceutical Holding Company LTD. | $97.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $93.16 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $83.85 | 2021 | |
| Lilly USA, LLC | $81.35 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.26 | 2021-2023 | Xifaxan, Trulance |
| Amgen INC. | $79.27 | 2021-2023 | Repatha |
| Esperion Therapeutics, INC. | $66.27 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $59.85 | 2019-2021 | |
| Abbott Laboratories | $57.76 | 2023 | Freestyle Libre 2 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lubna Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.